Our Pipeline

The programs in our portfolio are based on our deep expertise in the field of glycosylation and the role it plays in physiological and pathological cellular functions. Applying this skill, along with our understanding of computation biology/production of recombinant proteins and drug development, our core portfolio currently consists of programs at various stages of preclinical development that have the potential to transform the care of patients living with rare, life-threatening diseases.